BiopharmaTrend.com

A fresh viewpoint on drug discovery, pharma, and biotech

Subscribe | Become an author | Author LogIn

BiopharmaTrend Blog


Top AI in Pharma and Healthcare Conferences in 2019 You Can’t Miss

Top AI in Pharma and Healthcare Conferences in 2019 You Can’t Miss

Machine learning and artificial intelligence have become widely discussed topics in the area of life sciences and healthcare over the last several years. While a lot of pharmaceutical companies and healthcare organizations express considerable interest in possible new opportunities, associated with the use of artificial intelligence for early drug discovery, clinical trials optimization, and business intelligence, a considerable gap still exists when it comes to understanding new technologies by pharmaceutical professionals and leaders. The key questions here are these:

  • What machine learning / AI can and can’t do for pharmaceutical industry

  • What should be done to harness practical and measurable value out of machine learning / AI?

  • How it should be done and what are the timelines for getting returns on investments? 

2018: AI Is Surging In Drug Discovery Market

2018: AI Is Surging In Drug Discovery Market

The idea of using artificial intelligence (AI) to accelerate drug discovery process and boost a success rate of pharmaceutical research programs has inspired a surge of activity in this area over the last several years. In 2018, things are getting even “hotter” with the increase in the amount of partnerships, investments and other important events, summarized and grouped below into “mini-trends”.

How Big Pharma Adopts AI To Boost Drug Discovery

(Last updated 08.10.2018)

The type of artificial intelligence (AI) which scares some of the greatest minds, like Elon Musk and Stephen Hawking, is called “general artificial intelligence” -- the one which can “think” pretty much like humans do, and which can quickly evolve into a dangerous “superintelligence”. There is a notion that it might be invented in the nearest decades, but today we are definitely not there yet. The AI which is making headlines these days is a “narrow artificial intelligence”, a limited type of machine “intelligence” able to solve only a specific task or a group of tasks. It can’t go anywhere beyond specifics of the problem for which it is designed, so apparently, it will not hurt anyone in the nearest time. But already now it can provide meaningful practical results on those narrow tasks, like natural language processing, image recognition, controlling self-driving cars, and helping develop new drugs more efficiently. With the ability to find hidden and unintuitive patterns in vast amounts of data in ways that no human can do, AI represents a considerable promise to transform many industries, including pharma and biotech.  

Get Ready For “Super-platforms” In Healthcare and Pharmaceutical Research

Get Ready For “Super-platforms” In Healthcare and Pharmaceutical Research

What is a super-platform?

A “super-platform” is a term which describes a relatively new phenomenon in a modern technological world -- an online-to-offline (O2O) type of digital infrastructure, which spans across multiple sectors of economic activity providing a way for users (both businesses and consumers) to operate with multiple resources, products and services within a uniform, standardized, and highly interconnected way.

Imagine, you want to be able to search for information, shop online, pay for products and services, communicate with someone by email, or chat, create and manage text and spreadsheet documents, translate them into any language on the go, store and organize data like photos and videos, find local restaurants and get driving directions, or just entertain yourself by playing games -- and you prefer to have all of that in one place without needing to search for numerous websites and resources? You can do just that in your single Google account. This is what a super-platform does: it provides a way to conveniently engage in totally different types of activity across different sectors.

Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

Today Basel is crowded with some of the top business and research leaders representing a young and rapidly growing industry of artificial intelligence (AI) in healthcare and pharmaceutical research. They come together to announce mission and launch activities of a global Alliance for Artificial Intelligence in Healthcare (AAIH), which is to become a leading international organization for advancing artificial intelligence innovations in Drug Discovery, Clinical Research, Diagnostics, Precision Medicine and other key areas of pharmaceutical research and healthcare. The newly formed alliance will be a voice of the industry in matters of education, lobbying for policies and regulations, facilitating investment, and promoting AI-innovations among top drug makers and healthcare institutions.